Xaluritamig: new treatment for metastatic castration-resistant prostate cancer (mCRPC)

Categories: Winter 2023

A recent study presented at the European Society for Medical Oncology (ESMO) Congress in 2023 discussed a new treatment for patients with advanced prostate cancer. The research, led by Dr. William K. Kelly, examined the use of a treatment called xaluritamig in patients with metastatic castration-resistant prostate cancer (mCRPC).

The study aimed to assess the safety and effectiveness of xaluritamig in heavily treated mCRPC patients. This treatment targets a specific cell surface antigen called STEAP1, which is highly expressed in prostate cancer and is associated with worse prognosis. In preclinical studies, xaluritamig showed promise in attacking prostate cancer cells.

The researchers conducted a global, first-in-human study, including patients who had already undergone several prior therapies. They administered xaluritamig via intravenous doses at various levels and schedules. The results showed that the treatment was generally well-tolerated, with manageable side effects, including low-grade cytokine release syndrome, which is a form of systemic inflammatory response syndrome.

Encouragingly, the study revealed favorable responses in terms of PSA levels, with many patients showing a reduction in their PSA levels. There were also measurable disease responses, including partial responses and stable disease. Some patients had been on the treatment for more than six months, and the median duration of response was around 9.2 months. Dr. Kelly emphasized that while these results are promising, further research is needed to better understand the treatment’s overall clinical benefits, durability, and progression-free survival. The research supports the continued development of xaluritamig as a potential treatment option for patients with advanced prostate cancer, either as a stand-alone therapy or in combination with other treatments. This research offers hope for patients with metastatic castration-resistant prostate cancer, a condition with a poor prognosis.

Oncology Times. 2023, October 21




Subscribe to Quest

"*" indicates required fields


This email address is only for subscribing or unsubscribing to or from Quest. Dr. Catalona cannot respond to questions concerning your Personal Health Information (PHI) that could identify you as an individual. This is a "cyber-security measure" for your protection that will help prevent anyone from legally or illegally accessing your personal health information.

Delivery Method (How do you want to receive your Quest publication?)*